SunRegen Healthcare Email Formats

About SunRegen Healthcare

SunRegen Healthcare AG is a pioneering biopharmaceutical company based in the Basel Area, Switzerland, focused on developing innovative, neuroprotective, and neurorescuing therapies for ophthalmic and neurodegenerative diseases. Our lead candidate, SBC003, is a synthetic small molecule in late-stage preclinical development for conditions such as retinitis pigmentosa, glaucoma-related optic atrophy, and dry age-related macular degeneration-areas with significant unmet medical needs and limited current treatments. SBC003 is distinguished by its ability to cross the blood-brain and retinal barriers, oral bioavailability, and favorable safety profile. Preclinical studies have demonstrated both neuroprotective and neurorescuing effects, with evidence of structural and functional rescue in animal models and promising results in compassionate human use. SBC003 is also being evaluated for additional orphan neurological indications. Our dynamic team brings together passionate experts with proven track records in drug development, clinical research, and commercialization at leading pharmaceutical companies. SunRegen’s Scientific Advisory Board includes renowned neuroscientists and ophthalmology drug development leaders, and we collaborate with top academic and clinical institutions worldwide. Our achievements have been recognized with multiple industry awards and competitive grants, including support from the European Commission and Swiss government innovation agencies. As we advance toward clinical trials, SunRegen is dedicated to building strategic partnerships and engaging with investors who share our vision of transforming neurodegenerative disease treatment. Join us as we work to rescue and restore vision for patients in need.

View contact profiles from SunRegen Healthcare